Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

Abstract Background Measuring specific anti-SARS-CoV-2 antibodies has become one of the main epidemiological tools to survey the ongoing SARS-CoV-2 pandemic, but also vaccination response. The WHO made available a set of well-characterized samples derived from recovered individuals to allow normaliz...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Inge Kroidl, Simon Winter, Raquel Rubio-Acero, Abhishek Bakuli, Christof Geldmacher, Tabea M. Eser, Flora Déak, Sacha Horn, Anna Zielke, Mohamed I. M. Ahmed, Paulina Diepers, Jessica Guggenbühl, Jonathan Frese, Jan Bruger, Kerstin Puchinger, Jakob Reich, Philine Falk, Alisa Markgraf, Heike Fensterseifer, Ivana Paunovic, Angelika Thomschke, Michael Pritsch, Friedrich Riess, Elmar Saathoff, Michael Hoelscher, Laura Olbrich, Noemi Castelletti, Andreas Wieser, KoCo19/ORCHESTRA Study Group
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2023-09-01
coleção:	Virology Journal
Assuntos:	Antibody COVID-19 Nucleocapsid RBD SARS-CoV-2 Serology
Acesso em linha:	https://doi.org/10.1186/s12985-023-02167-z
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!